Johnson & Johnson JNJ will release earnings results for the first quarter before the opening bell on April 16, 2024.
Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings of $2.64 per share, up from $2.41 per share in the same period a year ago. Johnson & Johnson is expected to post quarterly revenue of $21.40 billion, up from $24.75 billion in the year-earlier quarter, according to data from Benzinga Pro.
Rallybio recently announced a collaboration with Johnson & Johnson to support the development of complementary therapeutic approaches to reduce the risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Johnson & Johnson shares rose 0.1% to close at $147.59 on Monday.
Benzinga readers can access the latest analyst ratings at Analyst stock ratings page. Readers can sort by stock title, company name, analyst firm, rating change or other variables.
Let’s look at how Benzinga is more accurate analysts rated the company in the recent period.
- Singer Fitzgerald Analyst Louise Chen reiterated an Overweight rating with a price target of $215 on April 15, 2024. This analyst has an accuracy rate of 62%.
- Morgan Stanley analyst Terence Flynn maintained an equal weight rating and cut his price target from $170 to $169 on January 24, 2024. This analyst has an accuracy rate of 69%.
- Raymond James analyst Jayson Bedford maintained an Outperform rating and raised his price target from $172 to $175 on January 3, 2024. This analyst has an accuracy rate of 68%.
- Wells Fargo analyst Larry Biegelsen downgraded the stock from Overweight to Equal-Weight and cut the price target from $170 to $163 on December 13, 2023. This analyst has an accuracy rate of 73%.
- UBS Analyst Danielle Antalffy upgraded the stock from Neutral to Buy with a price target of $180 on December 1, 2023. This analyst has an accuracy rate of 62%.
Read this next: Brightcove and 1 other Penny Stock insiders are buying
Market news and data powered by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.